DanDi Bioscience

ENG

DanDi Bioscience

KOR

NEWS

What’s new?

HOME
PR
NEWS
- Notice

No.	Title	Date
38	HLB Science Recognizes 'Health Care R&D Excellence' for Sepsis New Drug Technology	2023-01-13
37	Will HLB Science's stock price rebound with the entry into phase 1 clinical trials for sepsis treatm	2023-01-13
36	HLB Science, KRP Report (Kiwoom Securities)	2023-01-13
35	HLB Science, research agreement with Theranochem to develop anti-cancer drugs	2023-01-13
34	HLB Science. Seeking cooperation for innovative sepsis treatment in 'Bio Europe'	2023-01-13
33	HLB Science presented a poster at the Korean Society for Molecular and Cellular Biology	2023-01-13
32	HLB Science, xxxselected for excellence in healthcare R&D in 2022	2023-01-13
31	HLB Science announces preclinical results of sepsis treatment	2023-01-13
30	HLB Science, Sepsis Treatment France Phase 1 Clinical IND Approval	2023-01-13
29	HLB Science, 2022 KONEX science and technology innovation company relay IR held	2023-01-13

1
2
3
4

DanDi Bioscience

CEO of DanDi Bioscience Inc. : Yeong-Min Park / Jong-Sun Yoon Business license number : 677-88-00337 Ethical Management(Cyber Report)

CopyrightⓒHLB Science. ALL RIGHTS RESERVED